Photo from archive.org
To evaluate the long‐term efficacy and safety of lixisenatide, a short‐acting, prandial glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) as add‐on therapy in type 2 diabetes mellitus. Click to show full abstract
To evaluate the long‐term efficacy and safety of lixisenatide, a short‐acting, prandial glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) as add‐on therapy in type 2 diabetes mellitus.
Keywords:
type diabetes;
diabetes mellitus;
weeks treatment;
effect lixisenatide;
lixisenatide weeks;
beneficial effect
Journal Title: Diabetes
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Diabetes
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!